Adaptive Aerosol Delivery (AAD®) technology
| Autor: | N J Smith, Kurt Nikander, John Denyer |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Aerosols
Lung Diseases Drug medicine.medical_specialty Lung deposition business.industry Nebulizers and Vaporizers media_common.quotation_subject Pharmaceutical Science Pulmonary disease Equipment Design Pharmacology medicine.disease Aerosol delivery Drug Delivery Systems Pharmaceutical Preparations Administration Inhalation medicine Humans Technology Pharmaceutical Intensive care medicine business Asthma media_common |
| Zdroj: | Expert Opinion on Drug Delivery. 1:165-176 |
| ISSN: | 1744-7593 1742-5247 |
| DOI: | 10.1517/17425247.1.1.165 |
| Popis: | Jet nebulisers have, since the 1920s, been used for delivery of inhaled drugs for the treatment of asthma, chronic-obstructive pulmonary disease and pulmonary infections. During the last two decades, recognition of the shortcomings of conventional nebulisers has led to the development of new "intelligent" nebulisers such as the Adaptive Aerosol Delivery (AAD), Profile Therapeutics, a Respironics company) systems. Diseases of the airways have traditionally been logical candidates for treatment with inhaled drugs. The introduction of the "intelligent" nebulisers has, however, broadened the possibilities for inhaled treatment to include drugs targeted for systemic diseases. These nebulisers offer the possibility to deliver more precise doses of drug, maximise lung deposition, enhance adherence to treatment and compliance with the device through feedback to the patient, and last but not least, offer the possibility to reduce nebulisation times. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|